PMID- 21864750
OWN - NLM
STAT- MEDLINE
DCOM- 20120130
LR  - 20131121
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 93 Suppl 1
DP  - 2011 Aug
TI  - Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable 
      therapy?
PG  - S37-46
LID - 10.1016/S0168-8227(11)70012-2 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is characterised by beta-cell failure in the 
      setting of obesity-related insulin resistance. Progressive beta-cell dysfunction 
      determines the course of the disease, regardless of the treatment used. There is 
      mounting evidence that chronically elevated circulating levels of glucose and 
      fatty acids contribute to relentless beta-cell function decline, by endorsing 
      processes commonly referred to as glucolipotoxicity. Mechanisms related to 
      glucolipotoxicity include endoplasmic reticulum (ER) stress, oxidative stress, 
      mitochondrial dysfunction and islet inflammation. The most commonly prescribed 
      blood-glucose lowering agents, metformin and sul-fonylurea, may temporarily 
      improve glycaemic control, however, these drugs do not alter the continuous 
      decline in beta-cell function in T2DM patients. Evidence exists that novel 
      classes of drugs, the thiazolidinediones (TZDs) and incretin-based therapies, may 
      be able to preserve beta-cell function and functional beta-cell mass, amongst 
      others by reducing glucolipotoxicity in the beta cell. The durability of the 
      effects of TZDs and incretin-based therapies on beta-cell function, whether given 
      as monotherapy or combined with other treatment, should be addressed in future, 
      long-term clinical studies.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - van Raalte, Daniel H
AU  - van Raalte DH
AD  - Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, 
      Amsterdam, The Netherlands. d.vanraalte@vumc.nl
FAU - Diamant, Michaela
AU  - Diamant M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin-Secreting Cells/*drug effects/*metabolism
MH  - Metformin/therapeutic use
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Thiazolidinediones/therapeutic use
EDAT- 2011/09/01 06:00
MHDA- 2012/01/31 06:00
CRDT- 2011/08/26 06:00
PHST- 2011/08/26 06:00 [entrez]
PHST- 2011/09/01 06:00 [pubmed]
PHST- 2012/01/31 06:00 [medline]
AID - S0168-8227(11)70012-2 [pii]
AID - 10.1016/S0168-8227(11)70012-2 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S37-46. doi: 
      10.1016/S0168-8227(11)70012-2.